Predictive Oncology Q1 loss $2.3M; revenue up to $110k; cash position improves to $3.1M

Axe Compute Inc.

Net loss from continuing ops $2.3M ($0.32 per share) vs $0.88 loss per share YoY.
Revenue $110,310 vs $4,858 YoY, driven by completion of tumor-specific 3D model.
Cash and equivalents $3.1M at March 31, 2025, up from $611k at Dec 31, 2024.
Sold Skyline Medical assets to DeRoyal; sharpens focus on AI/ML drug discovery.
Plans European launch of ChemoFx assay for ovarian/gynecological cancers; expanded US availability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.